This protocol addresses classic hairy cell leukemia (HCL) actively requiring treatment — in a patient with no active infection and no renal impairment — where a prior course of relapse re-treatment failed to achieve the target response goals that define adequate disease control.
Classic HCL requiring intervention, confirmed in the absence of active infection and without renal impairment — both conditions directly relevant to the selection of appropriate therapy at each line of treatment.
A prior relapse re-treatment was undertaken — using purine analog-based re-treatment, optionally combined with an anti-CD20 monoclonal antibody or a clinical trial approach, depending on prior remission duration. That line aimed to achieve near normalization of peripheral blood counts (hemoglobin above 11 g/dL without transfusion; platelets above 100,000/mL; absolute neutrophil count above 1,500/mL) and regression of splenomegaly on physical examination. Failure to reach those goals is what escalates to the approach described here.
In this relapsed and refractory setting, management turns to investigational targeted agents — including therapies in the BRAF inhibitor class — among other options covered in the full protocol.
Increase in absolute neutrophil counts and achievement of complete remission.